BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology 2018;67:2449-59. [PMID: 29181853 DOI: 10.1002/hep.29685] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Reference Citation Analysis]
2 Wurcel AG, Reyes J, Zubiago J, Koutoujian PJ, Burke D, Knox TA, Concannon T, Lemon SC, Wong JB, Freund KM, Beckwith CG, LeClair AM. "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail. PLoS One 2021;16:e0250901. [PMID: 34038430 DOI: 10.1371/journal.pone.0250901] [Reference Citation Analysis]
3 Sakai Y, Fukunishi S, Takamura M, Kawaguchi K, Inoue O, Usui S, Takashima S, Seki A, Asai A, Tsuchimoto Y, Nasti A, Bich Ho TT, Imai Y, Yoshimura K, Murayama T, Yamashita T, Arai K, Yamashita T, Mizukoshi E, Honda M, Wada T, Harada K, Higuchi K, Kaneko S. Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. Regen Ther 2021;18:97-101. [PMID: 34095367 DOI: 10.1016/j.reth.2021.04.003] [Reference Citation Analysis]
4 Chang ML, Hu JH, Yen CH, Chen KH, Kuo CJ, Lin MS, Lee CH, Chen SC, Chien RN. Evolution of ferritin levels in hepatitis C patients treated with antivirals. Sci Rep. 2020;10:19744. [PMID: 33184464 DOI: 10.1038/s41598-020-76871-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Campo DS, Gussler JW, Sue A, Skums P, Khudyakov Y. Accurate spatiotemporal mapping of drug overdose deaths by machine learning of drug-related web-searches. PLoS One 2020;15:e0243622. [PMID: 33284864 DOI: 10.1371/journal.pone.0243622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Branch AD. Escape from planned obsolescence: Hepatitis C, the cirrhotic liver, and clonal expansions. J Exp Med 2020;217. [PMID: 33002101 DOI: 10.1084/jem.20191070] [Reference Citation Analysis]
7 Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Distefano M, Scifo G, Di Rosolini MA, Russello M, Prestileo T, Madonia S, Malizia G, Montineri A, Digiacomo A, Licata A, Benanti F, Bertino G, Enea M, Battaglia S, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J Viral Hepat 2021;28:1190-9. [PMID: 33896097 DOI: 10.1111/jvh.13523] [Reference Citation Analysis]
8 Miuma S, Miyamoto J, Taura N, Fukushima M, Sasaki R, Haraguchi M, Shibata H, Sato S, Miyaaki H, Nakao K. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis. Intern Med 2020;59:901-7. [PMID: 32238660 DOI: 10.2169/internalmedicine.3382-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jose R, Kahal D, Testa K, Goldstein ND; MBI4. A Qualitative Study of Implementing Universal Hepatitis C Screening Among Adults at an Urban Community-Based Health Provider in Delaware. Dela J Public Health 2021;7:16-23. [PMID: 34467206 DOI: 10.32481/djph.2021.07.006] [Reference Citation Analysis]
10 Li W, Chang TS, Chang SZ, Chen CH, Chen MY. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach. BMC Infect Dis 2020;20:737. [PMID: 33028228 DOI: 10.1186/s12879-020-05435-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Cook AK, Worcman N. Confronting the opioid epidemic: public opinion toward the expansion of treatment services in Virginia. Health Justice 2019;7:13. [PMID: 31338621 DOI: 10.1186/s40352-019-0095-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Hirose S, Yamaji Y, Tsuruya K, Ogawa Y, Miyaoka M, Kagawa T. Rapid Regression of B-Cell Non-Hodgkin's Lymphoma after Eradication of Hepatitis C Virus by Direct Antiviral Agents. Case Rep Gastroenterol 2019;13:336-41. [PMID: 31543755 DOI: 10.1159/000501546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Patel AA, Bui A, Prohl E, Bhattacharya D, Wang S, Branch AD, Perumalswami PV. Innovations in Hepatitis C Screening and Treatment. Hepatol Commun 2021;5:371-86. [PMID: 33681673 DOI: 10.1002/hep4.1646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bakhai S, Nallapeta N, El-Atoum M, Arya T, Reynolds JL. Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic. BMJ Open Qual 2019;8:e000577. [PMID: 31637319 DOI: 10.1136/bmjoq-2018-000577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Grosgebauer K, Bartholomew TS, Huynh K, Cos T. Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA. J Prim Prev 2021;42:203-15. [PMID: 33733379 DOI: 10.1007/s10935-021-00627-2] [Reference Citation Analysis]
17 Branch AD. How to Survive COVID-19 Even If the Vaccine Fails. Hepatol Commun 2020;4:1864-79. [PMID: 33305156 DOI: 10.1002/hep4.1588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS. Precision oncology in liver cancer. Ann Transl Med 2018;6:285. [PMID: 30105235 DOI: 10.21037/atm.2018.06.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
19 Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther 2021;38:423-40. [PMID: 33145648 DOI: 10.1007/s12325-020-01535-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
20 Salupo N, Cancilla L, Merryman S, Kaufhold J. The Grandview Medical Center Bioethics Consultation Service Perspective on the Peril of Isolated and Vulnerable Individuals due to COVID-19. Asian Bioeth Rev 2021;:1-9. [PMID: 34306211 DOI: 10.1007/s41649-021-00177-z] [Reference Citation Analysis]
21 Verma D, Ashkar C, Saab S. Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations. Expert Rev Pharmacoecon Outcomes Res 2021;21:9-12. [PMID: 33073620 DOI: 10.1080/14737167.2021.1838898] [Reference Citation Analysis]
22 Guo S, Kapp ME, Beltran DM, Cardona CY, Caster DJ, Reichel RR, Fogo AB. Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection. Am J Clin Pathol 2021;156:399-408. [PMID: 33623996 DOI: 10.1093/ajcp/aqaa238] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tong MJ, Theodoro CF, Salvo RT. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance: Late onset of HCC after HCV clearance. Journal of Digestive Diseases 2018;19:411-20. [DOI: 10.1111/1751-2980.12615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Saab S, Challita YP, Najarian LM, Guo R, Saggi SS, Choi G. Hepatitis C Screening: Barriers to Linkage to Care. J Clin Transl Hepatol. 2019;7:226-231. [PMID: 31608214 DOI: 10.14218/jcth.2018.00063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Sakai Y, Fukunishi S, Takamura M, Inoue O, Takashima S, Usui S, Seki A, Nasti A, Ho TTB, Kawaguchi K, Asai A, Tsuchimoto Y, Yamashita T, Yamashita T, Mizukoshi E, Honda M, Imai Y, Yoshimura K, Murayama T, Wada T, Harada K, Higuchi K, Kaneko S. Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial. JMIR Res Protoc 2020;9:e17904. [PMID: 32229470 DOI: 10.2196/17904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Verma M, Chu JN, Salama JAF, Faiz MT, Eweje F, Gwynne D, Lopes A, Hess K, Soares V, Steiger C, McManus R, Koeppen R, Hua T, Hayward A, Collins J, Tamang SM, Ishida K, Miller JB, Katz S, Slocum AH, Sulkowski MS, Thomas DL, Langer R, Traverso G. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Proc Natl Acad Sci U S A 2020;117:11987-94. [PMID: 32424082 DOI: 10.1073/pnas.2004746117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Tsay CJ, Lim JK. Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection. J Clin Transl Hepatol 2020;8:25-41. [PMID: 32274343 DOI: 10.14218/JCTH.2019.00059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]